The future of bronchodilation: looking for new classes of bronchodilators
Open Access
- 23 December 2019
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 28 (154) , 190095
Abstract
Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes.At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-γ; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.It is likely that if developed, these new classes may be a useful addition to, rather than a substitution of, the bronchodilator therapy currently used, in order to achieve further optimisation of bronchodilation.Keywords
This publication has 111 references indexed in Scilit:
- Rho-kinase inhibition attenuates airway responsiveness, inflammation, matrix remodeling, and oxidative stress activation induced by chronic inflammationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug DevelopmentJournal of Biological Chemistry, 2012
- The Minimal Active Structure of Human Relaxin-2Journal of Biological Chemistry, 2011
- EP4 receptor as a new target for bronchodilator therapyThorax, 2011
- Rosiglitazone reverses salbutamol‐induced β2‐adrenoceptor tolerance in airway smooth muscleBritish Journal of Pharmacology, 2010
- Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstructionNature Medicine, 2010
- A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in miceRespiratory Research, 2009
- Tonic activity of Gα‐gustducin regulates taste cell responsivityFEBS Letters, 2008
- Novel long‐acting bronchodilators for COPD and asthmaBritish Journal of Pharmacology, 2008
- Alternative splicing of the G protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptorsProceedings of the National Academy of Sciences, 2008